Chemomab CEO Dale Pfost expected to become chairman; Stephen Squinto resigns as chairman and director

Chemomab Therapeutics Ltd.

Stephen Squinto resigns as chairman and director effective Dec 19, 2021; decision not due to any disagreement with company.
CEO Dale Pfost, PhD expected to become chairman subject to shareholder vote in or around February 2022.
Planned succession; Squinto's term was set to lapse by June 2022; transition accelerated to Dec 2021.
Company advancing Phase 2 programs in primary sclerosing cholangitis, liver fibrosis; Phase 2 trial in systemic sclerosis planned.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stephen Squinto

Chairman of the Board

CMMB · Chemomab Therapeutics Ltd.

Effective: 2021-12-19
Successor: Dale Pfost
Filed: December 16, 2021, 6:59 PM ET

On December 12, 2021, the Company and Mr. Squinto mutually agreed that Mr. Squinto’s resignation as the chairman of the Board will enter into effect on December 19, 2021.

Appointed

Dale Pfost

Chairman of the Board

CMMB · Chemomab Therapeutics Ltd.

Filed: December 16, 2021, 6:59 PM ET

the nominating and governance committee and the Board each approved and recommended that the shareholders approve the appointment of Dr. Pfost as chairman of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Squinto resigned as Chairman of the Board at Chemomab Therapeutics Ltd..

Action: resigned
Role: Chairman of the Board

Exact text from the filing

On December 12, 2021, the Company and Mr. Squinto mutually agreed that Mr. Squinto’s resignation as the chairman of the Board will enter into effect on December 19, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.85

Dale Pfost was appointed as Chairman of the Board at Chemomab Therapeutics Ltd..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

the nominating and governance committee and the Board each approved and recommended that the shareholders approve the appointment of Dr. Pfost as chairman of the Board.

View on SEC.gov

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-21-003880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.